On the basis of art.27, par.1. it. 2 of the Ordinance No. 2 of the Financial Supervision Commission (FSC), we notify the following circumstances relating to Tchaikapharma High Quality Medicines Inc., which constitute “internal information” within the meaning of Art. 4 of the Law Against Market Abuse with Financial Instruments and Ordinance No. 2 of FSC, namely:
In execution of the provisions in Chapter eight, General section, article 116d from The Public Offering of Securities Act, Tchaikapharma High Quality Medicines Inc. in its role as a public company and as an issuer of securities, announces that as of April 4th 2017 Anastas Patarinski is appointed under a labor contract as the new Investment Relations Director.